Abstract
Cancer cells are known to drastically alter cellular energy metabolism. The Warburg effect has been known for over 80 years as pertaining cancer-specific aerobic glycolysis. As underlying molecular mechanisms are elucidated so that cancer cells alter the cellular energy metabolism for their advantage, the significance of the modulation of metabolic profiles is gaining attention. Now, metabolic reprogramming is becoming an emerging hallmark of cancer. Therapeutic agents that target cancer energy metabolism are under intensive investigation, but these investigations are mostly focused on the cytosolic glycolytic processes. Although mitochondrial oxidative phosphorylation is an integral part of cellular energy metabolism, until recently, it has been regarded as an auxiliary to cytosolic glycolytic processes in cancer energy metabolism. In this review, we will discuss the importance of mitochondrial respiration in the metabolic reprogramming of cancer, in addition to discussing the justification for using mitochondrial DNA somatic mutation as metabolic determinants for cancer sensitivity in glucose limitation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Siegel, R., Ma, J., Zou, Z. and Jemal, A. (2014) Cancer statistics, 2014. Ca Cancer J. Clin., 64, 9–29.
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646–674.
Cantor, J.R. and Sabatini, D.M. (2012) Cancer cell metabolism: one hallmark, many faces. Cancer Discovery, 2, 881– 898.
Chen, X., Qian, Y. and Wu, S. (2014) The warburg effect: Evolving interpretations of an established concept. Free Radical Biol. Med., Epub ahead of print.
Phan, L.M., Yeung, S.C. and Lee, M.H. (2014) Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol. Med., 11, 1–19.
Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell, 100, 57–70.
Warburg, O.H. (1930) The Metabolism of Tumours: Investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem. Arnold Constable, London, pp. 1–327.
Koppenol, W.H., Bounds, P.L. and Dang, C.V. (2011) Otto Warburg’s contributions to current concepts of cancer metabolism. Nat. Rev. Cancer, 11, 325–337.
Rask-Andersen, M., Zhang, J., Fabbro, D. and Schioth, H.B. (2014) Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol. Sci., 35, 604–620.
Nahta, R. and Esteva, F.J. (2007) Trastuzumab: triumphs and tribulations. Oncogene, 26, 3637–3643.
Ramos, P. and Bentires-Alj, M. (2014) Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene, Epub ahead of print.
Garber, K. (2006) Energy deregulation: licensing tumors to grow. Science, 312, 1158–1159.
Vander Heiden, M.G., Cantley, L.C. and Thompson, C.B. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029–1033.
Granchi, C., Fancelli, D. and Minutolo, F. (2014) An update on therapeutic opportunities offered by cancer glycolytic metabolism. Bioorg. Med. Chem. Lett., 24, 4915–4925.
Pathania, D., Millard, M. and Neamati, N. (2009) Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv. Drug Delivery Rev., 61, 1250–1275.
Bellance, N., Lestienne, P. and Rossignol, R. (2009) Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front. Biosci. (Landmark Ed.), 14, 4015–4034.
Seyfried, T.N., Flores, R.E., Poff, A.M. and D’Agostino, D.P. (2014) Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis, 35, 515–527.
Coller, H.A. (2014) Is cancer a metabolic disease? Am. J. Pathol., 184, 4–17.
Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R. and Morris, A.D. (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304–1305.
Pernicova, I. and Korbonits, M. (2014) Metformin--mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol., 10, 143–156.
Menendez, J.A., Quirantes-Piné, R., Rodríguez-Gallego, E., Cufí, S., Corominas-Faja, B., Cuyàs, E., Bosch-Barrera, J., Martin-Castillo, B., Segura-Carretero, A. and Joven, J. (2014) Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget, 5, 2344–2348.
Bridges, H.R., Jones, A.J., Pollak, M.N. and Hirst, J. (2014) Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J., 462, 475–487.
Pessayre, D., Fromenty, B., Berson, A., Robin, M.A., Lettéron, P., Moreau, R. and Mansouri, A. (2012) Central role of mitochondria in drug-induced liver injury. Drug Metab. Rev., 44, 34–87.
Szczepanek, K., Chen, Q., Larner, A.C. and Lesnefsky, E.J. (2012) Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3. Mitochondrion, 12, 180–189.
Vaupel, P., Hockel, M. and Mayer, A. (2007) Detection and characterization of tumor hypoxia using pO2 histography. Antioxid. Redox Signaling, 9, 1221–1235.
Hirayama, A., Kami, K., Sugimoto, M., Sugawara, M., Toki, N., Onozuka, H., Kinoshita, T., Saito, N., Ochiai, A., Tomita, M., Esumi, H. and Soga, T. (2009) Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res., 69, 4918–4925.
Birsoy, K., Possemato, R., Lorbeer, F.K., Bayraktar, E.C., Thiru, P., Yucel, B., Wang, T., Chen, W.W., Clish, C.B. and Sabatini, D.M. (2014) Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature, 508, 108–112.
McKenzie, M., Liolitsa, D. and Hanna, M.G. (2004) Mitochondrial disease: mutations and mechanisms. Neurochem. Res., 29, 589–600.
Salminen, A., Ojala, J., Kaarniranta, K. and Kauppinen, A. (2012) Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell. Mol. Life Sci., 69, 2999–3013.
Bonora, E., Porcelli, A.M., Gasparre, G., Biondi, A., Ghelli, A., Carelli, V., Baracca, A., Tallini, G., Martinuzzi, A., Lenaz, G., Rugolo, M. and Romeo, G. (2006) Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res., 66, 6087–6096.
Szablewski, L. (2013) Expression of glucose transporters in cancers. Biochim. Biophys. Acta, 1835, 164–169.
Zhang, X., Fryknäs, M., Hernlund, E., Fayad, W., De Milito, A., Olofsson, M.H., Gogvadze, V., Dang, L., Påhlman, S., Schughart, L.A., Rickardson, L., D’Arcy, P., Gullbo, J., Nygren, P., Larsson, R. and Linder, S. (2014) Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat. Commun., 5, 3295.
Viale, A., Pettazzoni, P., Lyssiotis, C.A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., Kost-Alimova, M., Muller, F., Colla, S., Nezi, L., Genovese, G., Deem, A.K., Kapoor, A., Yao, W., Brunetto, E., Kang, Y., Yuan, M., Asara, J.M., Wang, Y.A., Heffernan, T.P., Kimmelman, A.C., Wang, H., Fleming, J.B., Cantley, L.C., DePinho, R.A. and Draetta, G.F. (2014) Oncogene ablationresistant pancreatic cancer cells depend on mitochondrial function. Nature, 514, 628–632.
Le, A., Stine, Z.E., Nguyen, C., Afzal, J., Sun, P., Hamaker, M., Siegel, N.M., Gouw, A.M., Kang, B.H., Yu, S.H., Cochran, R.L., Sailor, K.A., Song, H. and Dang, C.V. (2014) Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxiacell cycle dual reporter. Proc. Natl. Acad. Sci. U.S.A., 111, 12486–12491.
Osada-Oka, M., Hashiba, Y., Akiba, S., Imaoka, S. and Sato, T. (2010) Glucose is necessary for stabilization of hypoxiainducible factor-1alpha under hypoxia: contribution of the pentose phosphate pathway to this stabilization. FEBS Lett., 584, 3073–3079.
Semenza, G.L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3, 721–732.
Gasparre, G., Porcelli, A.M., Lenaz, G. and Romeo, G. (2013) Relevance of mitochondrial genetics and metabolism in cancer development. Cold Spring Harbor Perspect. Biol., 5, a011411.
Pike Winer, L.S. and Wu, M. (2014) Rapid analysis of glycolytic and oxidative substrate flux of cancer cells in a microplate. PLoS One, 9, e109916.
Habano, W., Sugai, T., Yoshida, T. and Nakamura, S. (1999) Mitochondrial gene mutation, but not large-scale deletion, is a feature of colorectal carcinomas with mitochondrial microsatellite instability. Int. J. Cancer, 83, 625–629.
Jerónimo, C., Nomoto, S., Caballero, O.L., Usadel, H., Henrique, R., Varzim, G., Oliveira, J., Lopes, C., Fliss, M.S. and Sidransky, D. (2001) Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene, 20, 5195–5198.
Máximo, V., Soares, P., Lima, J., Cameselle-Teijeiro, J. and Sobrinho-Simões, M. (2002) Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am. J. Pathol., 160, 1857–1865.
Costa-Guda, J., Tokura, T., Roth, S.I. and Arnold, A. (2007) Mitochondrial DNA mutations in oxyphilic and chief cell parathyroid adenomas. BMC Endocr. Disord., 7, 8.
Gasparre, G., Porcelli, A.M., Bonora, E., Pennisi, L.F., Toller, M., Iommarini, L., Ghelli, A., Moretti, M., Betts, C.M., Martinelli, G.N., Ceroni, A.R., Curcio, F., Carelli, V., Rugolo, M., Tallini, G. and Romeo, G. (2007) Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc. Natl. Acad. Sci. U.S.A., 104, 9001–9006.
Gasparre, G., Hervouet, E., de Laplanche, E., Demont, J., Pennisi, L.F., Colombel, M., Mège-Lechevallier, F., Scoazec, J.Y., Bonora, E., Smeets, R., Smeitink, J., Lazar, V., Lespinasse, J., Giraud, S., Godinot, C., Romeo, G. and Simonnet, H. (2008) Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum. Mol. Genet., 17, 986–995.
Dasgupta, S., Koch, R., Westra, W.H., Califano, J.A., Ha, P.K., Sidransky, D. and Koch, W.M. (2010) Mitochondrial DNA mutation in normal margins and tumors of recurrent head and neck squamous cell carcinoma patients. Cancer Prev. Res. (Philadelphia), 3, 1205–1211.
Porcelli, A.M., Ghelli, A., Ceccarelli, C., Lang, M., Cenacchi, G., Capristo, M., Pennisi, L.F., Morra, I., Ciccarelli, E., Melcarne, A., Bartoletti-Stella, A., Salfi, N., Tallini, G., Martinuzzi, A., Carelli, V., Attimonelli, M., Rugolo, M., Romeo, G. and Gasparre, G. (2010) The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization. Hum. Mol. Genet., 19, 1019–1032.
Ye, F., Samuels, D.C., Clark, T. and Guo, Y. (2014) High-throughput sequencing in mitochondrial DNA research. Mitochondrion, 17, 157–163.
Singh, A.K., Pandey, P., Tewari, M., Pandey, H.P. and Shukla, H.S. (2014) Human mitochondrial genome flaws and risk of cancer. Mitochondrial DNA, 25, 329–334.
Damas, J., Samuels, D.C., Carneiro, J., Amorim, A. and Pereira, F. (2014) Mitochondrial DNA rearrangements in health and disease--a comprehensive study. Hum. Mutat., 35, 1–14.
Ju, Y.S., Alexandrov, L.B., Gerstung, M., Martincorena, I., Nik-Zainal, S., Ramakrishna, M., Davies, H.R., Papaemmanuil, E., Gundem, G., Shlien, A., Bolli, N., Behjati, S., Tarpey, P.S., Nangalia, J., Massie, C.E., Butler, A.P., Teague, J.W., Vassiliou, G.S., Green, A.R., Du, M.Q., Unnikrishnan, A., Pimanda, J.E., Teh, B.T., Munshi, N., Greaves, M., Vyas, P., El-Naggar, A.K., Santarius, T., Collins, V.P., Grundy, R., Taylor, J.A., Hayes, D.N., Malkin, D., Foster, C.S., Warren, A.Y., Whitaker, H.C., Brewer, D., Eeles, R., Cooper, C., Neal, D., Visakorpi, T., Isaacs, W.B., Bova, G.S., Flanagan, A.M., Futreal, P.A., Lynch, A.G., Chinnery, P.F., McDermott, U., Stratton, M.R. and Campbell, P.J. (2014) Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. eLife, 3, e02935.
Jones, J.B., Song, J.J., Hempen, P.M., Parmigiani, G., Hruban, R.H. and Kern, S.E. (2001) Detection of mitochondrial DNA mutations in pancreatic cancer offers a “mass”-ive advantage over detection of nuclear DNA mutations. Cancer Res., 61, 1299–1304.
Lai, C.H., Huang, S.F., Liao, C.T., Chen, I.H., Wang, H.M. and Hsieh, L.L. (2013) Clinical significance in oral cavity squamous cell carcinoma of pathogenic somatic mitochondrial mutations. PLoS One, 8, e65578.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Kim, A. Mitochondrial DNA Somatic Mutation in Cancer. Toxicol Res. 30, 235–242 (2014). https://doi.org/10.5487/TR.2014.30.4.235
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2014.30.4.235